Trial document

drksid header


Trial Description

start of 1:1-Block title


AXINAB AXirubicin-e® IN Adjuvant Breast Cancer
Non - interventional study on the efficacy and tolerability of epirubicin in the treatment of
breast cancer

end of 1:1-Block title
start of 1:1-Block acronym

Trial Acronym


end of 1:1-Block acronym
start of 1:1-Block url

URL of the Trial


end of 1:1-Block url
start of 1:1-Block public summary

Brief Summary in Lay Language

In this prospective non-interventional study no recommendation is made for diagnosis, treatment, enforcement and ongoing study conduct. Non-interventional studies are intended to reflect the actual treatment procedure and its results. This study was reported by axios Pharma GmbH according to § 67 paragraph 6 of the AMG (German Drug Law) to the BfArM (Study No 2076) and relevant institutions defined there (GKV, PKV, KBV). A list of participating doctors and sites is thereby transmitted at regular intervals and is going to be updated. Due to legal requirements pharmaceuticals used in non-interventional trials must not be provided as pharmaceutical samples.
For quality assurance monitoring visits can take place at sites which are chosen randomly here and without the influence of axios Pharma GmbH. This non-interventional study was submitted prior to your start of an ethics committee and positive.
The AXINAB trial is a non-interventional study ( NIS). In the CRF all variables are are recorded, which could be relevant for subsequent evaluation and analysis. If parameters listed in CRF are not assessed in local practice of routine they will not be questioned, since it is the main objective of this trial to reflect the variation of local standards of care. Last but not least study participation is independent from treatment decision. This means, a patient should be included only after decision for a certain therapy and in accordance with the SPC.
The objective of this non-interventional study is to evaluate the efficacy, tolerability and side-effect profile of epirubicin, in this case axirubicin-e ®, in daily practice under routine conditions. Patients for whom therapy with this preparation according to the SPC is a therapy option and who meet the inclusion and exclusion criteria of this non-interventional study (NIS-AWB) are eligible. Besides the SPC listed safety and efficacy information this trial will focus on additional aspects of interest which were not or only partly addressed in trials leading to marketing authorization. These study specific target questions are listed below.

end of 1:1-Block public summary
start of 1:1-Block scientific synopsis

Brief Summary in Scientific Language

Besides the already known SPC listed information regarding safety and efficacy the following target questions are going to be addressed:

- What regimens including dosing with epirubicin are used in practice routine qualitatively, meaning what kind of combinations are observed , and quantitatively, meaning what are their percentages?

- To what extent has the infusion rate administered according to local standard of care influence on therapy response and cardiovascular toxicity assessed by ECG and echocardiography ( LEFV )?

- To what extent are patients with reduced performance status (ECOG ) or of advanced age (> 70 ) more affected by side effects than patients with lower age and better general condition ?

- Are there unknown side effects not observed so far or has the frequency pattern of already known side effects to be revised?

- How do antiemetic and supportive concomitant medications influence the tolerability and the frequency of therapy specific side effects?

The study design of a non-interventional study appears to be suitable in order to answer the questions outlined above especially when they are investigated in a routine practice setting. Therefore, this protocol does not include any instructions, except SPC, in order to reflect the current standard of care use. E.g. no recommendations are specified in terms of dosing, patient clientele, treatment regimens and treatment intervals.

end of 1:1-Block scientific synopsis
start of 1:1-Block organizational data

Organizational Data

  •   DRKS00006019
  •   2014/03/21
  •   [---]*
  •   no
  •   Approved
  •   Bo/43/2013, Ethikkommission bei der Ärztekammer Niedersachsen
end of 1:1-Block organizational data
start of 1:n-Block secondary IDs

Secondary IDs

  • [---]*
end of 1:n-Block secondary IDs
start of 1:N-Block indications

Health Condition or Problem studied

  •   C50 -  Malignant neoplasm of breast
  •   Side effects of chemotherapy with Axirubicin-e with a focus on cardiotoxicity and impaired quality of life.
end of 1:N-Block indications
start of 1:N-Block interventions

Interventions/Observational Groups

  •   Ca. 600 patients will be observed with newly diagnosed or secondary cancer breast cancer over a recruitment period of a total of 5 years. Approximately 40-50 oncology practices and selected outpatient clinics will participate. The individual observation period per patient in this case comprises the entire adjuvant chemotherapy and follow-up visits every 6 months over a period of at least 2 years.
    The observation is carried out prospectively , therefore therapy starts after enrollment in this study.

    All data must be strictly in accordance with the existing source data (file, lab results , etc. ). About 5% of the data will be reviewed by clinical monitors for reasons of quality assurance. Not assessed parameters will not be followed up in order to keep the approach of a non-interventional study. These parameters will be documented as “not done”. Documentation should be performed in a timely manner within a time frame of 12 weeks after assessment which will enable early detection of safety issues. Timely documentation increases also the data quality significantly and allows study-accompanying interim analyzes .
    Serious adverse events (SAE) and pregnancies are to be reported within 24 hours of becoming aware. Pregnancy is also to be reported up to 90 days after end of therapy. Methods of documentation comprise the enrollment form, demographic data including ECOG and Karnofsky Index, baseline anamnestic data of the underlying disease like TNM-staging, grading and tumor markers, medical history, concomitant diseases and medications, anamnestic data of tumor, current therapy data, end of therapy and follow-up visits based on a state of the art CRF for oncologic trials.

end of 1:N-Block interventions
start of 1:1-Block design


  •   Non-interventional
  •   Observational study
  •   Single arm study
  •   Open (masking not used)
  •   [---]*
  •   Uncontrolled/Single arm
  •   Treatment
  •   Single (group)
  •   IV
  •   N/A
end of 1:1-Block design
start of 1:1-Block primary endpoint

Primary Outcome

Locally differentiated use of Axirubicin-e in anti-cancer regimens

end of 1:1-Block primary endpoint
start of 1:1-Block secondary endpoint

Secondary Outcome

Additional data regarding the safety profile of AXirubicin-e

end of 1:1-Block secondary endpoint
start of 1:n-Block recruitment countries

Countries of Recruitment

  •   Germany
end of 1:n-Block recruitment countries
start of 1:n-Block recruitment locations

Locations of Recruitment

  • other 
end of 1:n-Block recruitment locations
start of 1:1-Block recruitment


  •   Actual
  •   2014/03/24
  •   600
  •   Multicenter trial
  •   National
end of 1:1-Block recruitment
start of 1:1-Block inclusion criteria

Inclusion Criteria

  •   Female
  •   18   Years
  •   no maximum age
end of 1:1-Block inclusion criteria
start of 1:1-Block inclusion criteria add

Additional Inclusion Criteria

- Diagnosed breast cancer for which Axirubicin-e represents a therapeutic option according to SPC
- Informed Consent including data protection informed consent

end of 1:1-Block inclusion criteria add
start of 1:1-Block exclusion criteria

Exclusion Criteria

Not applicable

end of 1:1-Block exclusion criteria
start of 1:n-Block addresses


  • start of 1:1-Block address primary-sponsor
    • Axios Pharma Gmbh
    • Mr.  Wolfgang  Seppich 
    • Kammerichstrasse 39
    • 33647  Bielefeld
    • Germany
    end of 1:1-Block address primary-sponsor
    start of 1:1-Block address contact primary-sponsor
    end of 1:1-Block address contact primary-sponsor
  • start of 1:1-Block address primary-sponsor
    • Axios Pharma Gmbh
    • Mr.  Wolfgang  Seppich 
    • Kammerichstrasse 39
    • 33647  Bielefeld
    • Germany
    end of 1:1-Block address primary-sponsor
    start of 1:1-Block address contact primary-sponsor
    end of 1:1-Block address contact primary-sponsor
  • start of 1:1-Block address scientific-contact
    • Datafaber GbR
    • Dr  Burkard  Heckelbacher 
    • Kantstrasse 15
    • 85356  Freising
    • Germany
    end of 1:1-Block address scientific-contact
    start of 1:1-Block address contact scientific-contact
    end of 1:1-Block address contact scientific-contact
  • start of 1:1-Block address public-contact
    • Axios Pharma Gmbh
    • Mr.  Wolfgang  Seppich 
    • Kammerichstrasse 39
    • 33647  Bielefeld
    • Germany
    end of 1:1-Block address public-contact
    start of 1:1-Block address contact public-contact
    end of 1:1-Block address contact public-contact
end of 1:n-Block addresses
start of 1:n-Block material support

Sources of Monetary or Material Support

  • start of 1:1-Block address materialSupport
    • Axios Pharma Gmbh
    • Mr.  Wolfgang  Seppich 
    • Kammerichstr. 39
    • 33647  Bielefeld
    • Germany
    end of 1:1-Block address materialSupport
    start of 1:1-Block address contact materialSupport
    end of 1:1-Block address contact materialSupport
end of 1:n-Block material support
start of 1:1-Block state


  •   Recruiting complete, follow-up continuing
  •   [---]*
end of 1:1-Block state
start of 1:n-Block publications

Trial Publications, Results and other Documents

end of 1:n-Block publications
* This entry means the parameter is not applicable or has not been set.